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ABSTRACT
Objective Due to a high efficacy in clinical trials,
sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks
is recommended for treatment of patients with HCV
genotype (GT) 2 infection. We investigated safety and
effectiveness of these regimens for GT2 in HCV-TARGET
participants.
Design HCV-TARGET, an international, prospective
observational study evaluates clinical practice data on
novel antiviral therapies at 44 academic and 17
community medical centres in North America and
Europe. Clinical data were centrally abstracted from
medical records. Selection of treatment regimen and
duration was the investigator’s choice. The primary
efficacy outcome was sustained virological response
12 weeks after therapy (SVR12).
Results Between December 2013 and April 2015, 321
patients completed 12 weeks (n=283) or 16 weeks
(n=38) of treatment with SOF and RBV. Prior treatment
experience and cirrhosis was more frequent among
patients in the 16-week regimen compared with
12 weeks (52.6% vs 27.6% and 63.2% vs 21.9%,
respectively). Overall, SVR12 was 88.2%. The SVR12 in
patients without cirrhosis was 91.0% and 92.9% for 12
or 16 weeks of therapy, respectively. In patients with
cirrhosis treated for 12 or 16 weeks, SVR12 was 79.0%
and 83%. In the multivariate analysis, liver cirrhosis,
lower serum albumin and RBV dose at baseline were
significantly associated with SVR12. Common adverse
events (AEs) included fatigue, anaemia, nausea,
headache, insomnia, rash and flu-like symptoms.
Discontinuation due to AEs occurred in 2.8%.
Conclusions In this clinical practice setting, SOF and
RBV was safe and effective for treatment of patients
with HCV GT2 infection.
Trial registration number NCT01474811.
INTRODUCTION
Chronic infection with HCV is a major cause of
end-stage liver disease and hepatocellular
Significance of this study
What is already known on this subject?
▸ Due to a high efficacy in clinical trials, the
all-oral combination of sofosbuvir (SOF) and
ribavirin (RBV) for 12 weeks is currently
considered standard of care in patients with
HCV genotype 2 (GT2) infection.
▸ Based on limited data from clinical trials,
treatment extension to 16 weeks is
recommended by international HCV treatment
guidelines for patients with negative predictors
of treatment response, including patients with
liver cirrhosis.
▸ Information on the effectiveness and safety of
SOF and RBV for treatment of HCV GT2 in
real-world, clinical practice is limited.
What are the new findings?
▸ Sustained virological response 12 weeks after
therapy (SVR12) rates as observed in
HCV-TARGET, a prospective, international,
multicentre ‘real-word’ study that included a
larger number of patients with HCV GT2
infection than any pivotal study generally
confirm the effectiveness and safety of SOF and
RBV for treatment of GT2.
▸ While response rates in patients without
cirrhosis were high and comparable with those
reported in clinical trials, liver cirrhosis, lower
serum albumin levels and RBV dose at baseline
were associated with lower SVR12 rates.
▸ Only a small proportion of patients with
cirrhosis (27%) were treated for 16 weeks, and
response rates were similar to those treated for
12 weeks. Larger, randomised and adequately
powered trials would be necessary to assess
the benefit of treatment extension to 16 weeks
in cirrhotics.
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carcinoma (HCC).1 2 Sustained virological response 12 weeks
after therapy (SVR12) is associated with a decreased risk for
liver-related morbidity and mortality.3 4
Among the seven HCV genotypes (GTs) isolated until now,
HCV genotype 2 (GT2) is the third most common GTwith an
estimated 16.5 million GT2-infected persons worldwide.
Relative proportions of HCV GT2 infections range from 10.8%
and 12% in Western Europe and North America to higher pre-
valences in Central Latin America (19.3%), Western
Sub-Saharan Africa (23.0%) and Asia Pacific (24.5%).5 6
Compared with other HCV GTs such as GT1, GT3 and GT4,
historic therapy with pegylated interferon (PegIFN) and riba-
virin (RBV) for 24 weeks yielded favourable response rates in
GT2-infected patients.7 However, the poor tolerability limited
the clinical use of PegIFN-based therapies, in particular in
patients with liver cirrhosis.
The availability of all-oral, direct-acting antiviral (DAA) drug
combinations with high efficacy, favourable side-effect profile
and easy applicability facilitated treatment of HCV infection in
clinical practice.8 9 Sofosbuvir (SOF), a first in-class nucleotide
NS5B polymerase inhibitor with a high barrier to resistance,
was approved for interferon-free treatment of HCV infection in
the USA and Europe in early 2014.10
For HCV GT2, the efficacy and safety of SOF in combination
with weight-based RBV for 12 weeks was investigated in several
pivotal phase III trials: FISSION, POSITRON and
VALENCE.11–13 In these trials, 94% of patients without cirrho-
sis and 90% of patients with cirrhosis achieved a SVR12.
Another phase III study (FUSION) that compared SOF and RBV
for 12 or 16 weeks indicated that patients with liver cirrhosis
may benefit from extended treatment duration.12 This study,
however, only included a small number of patients with cirrho-
sis; SVR12 rates were 60% and 78% in patients treated for 12
and 16 weeks, respectively. Based on these results, SOF and
RBV for 12 weeks is currently recommended for most patients
with HCV GT2 infection by US, Canadian and European guide-
lines, although extension to 16 weeks may be considered for
patients with cirrhosis.14–17
Information derived from usual clinical practice on treatment
of HCV GT2 with SOF and RBV is limited18 19 and outcomes
in selected study populations may differ from those observed in
clinical practice. The aim of this study was to investigate the
effectiveness and tolerability of SOF and RBV for treatment of
HCV GT2 in HCV-TARGET, an international, prospective
observational academic consortium study, designed to evaluate
information on novel DAA therapies used in routine patient
care.20
MATERIALS AND METHODS
Patients
HCV-TARGET is a prospective, longitudinal, observational
study conducted at 44 academic and 17 community medical
centres in North America (57 centres) and Europe (4 centres).
The registry enrolls adult patients with HCV (≥18 years), who
initiated HCV treatment with DAA agents according to the rec-
ommendation of the site investigator. For participation, patients
had to provide informed consent within 4 weeks after treatment
initiation. This study includes data from patients with HCV
GT2 infection sequentially enrolled in HCV-TARGET between
8 December 2013 and 15 April 2015. Patients completed treat-
ment with SOF and weight-based RBV for a duration of either
12 or 16 weeks (with a duration window of ±2 weeks to
account for practice variability). Patients were excluded from
this analysis if they had undergone liver transplantation or had
previously been treated with a prior DAA.
Treatments
SOF was prescribed at an oral standard dose of 400 mg once
daily. Selection of the appropriate RBV dose and determination
of the treatment duration were the physician’s choice. According
to the label, the recommended RBV dose is 1000 mg/day
(≤75 kg) or 1200 (>75 kg) mg/day, divided into two daily doses.
Data collection
Demographic and clinical information, laboratory tests and
technical exams were performed according to the site’s stan-
dards. Data were collected within a centralised database using
standardised source data abstraction as described previously.21
The database was managed using Research Electronic Data
Capture (REDCap) tools hosted at the University of North
Carolina, Chapel Hill.22 To optimise data quality, a trained
Centralized Chart Data Abstraction Team at the Clinical
Coordinating Center at the University of Florida was established
to enter de-identified copies of source data, that is, clinical
records that were provided by participating sites. Special effort
was made to explore reasons for premature discontinuations
and to investigate the reasons for missing data and to minimise
loss to follow-up. Independent data monitors reviewed data
entries for completeness and accuracy.
Cirrhosis status was assessed by availability of a liver biopsy
or a combination of several clinical and/or imaging criteria pre-
viously described.21 Briefly, cirrhosis was defined by (1) liver
biopsy indicating liver fibrosis stage 4 (Metavir) prior to treat-
ment initiation and (2) liver biopsy indicating stage 3 fibrosis
prior to treatment initiation in combination with any of the fol-
lowing clinical parameters: platelets <140 000/mL, oesophageal
varices on oesophagogastroduodenoscopy, cirrhosis and/or
portal hypertension and/or of ascites by imaging methods,
FibroSure (or equivalent) test, vibration-controlled transient
elastography (VCTE) or equivalent compatible with fibrosis
stage 4. If a liver biopsy was not available, cirrhosis was defined
by evidence for two of the following variables: platelet count
<140 000/mL, evidence for oesophageal varices on oesophago-
gastroduodenoscopy, cirrhosis and/or portal hypertension and/
or ascites as diagnosed by imaging studies, FibroSure or equiva-
lent test, VCTE or equivalent compatible with stage 4 fibrosis.
Decompensated cirrhosis was defined as the presence of current
or past ascites, hepatic encephalopathy, spontaneous bacterial
peritonitis, hepatic hydrothorax, variceal haemorrhage or con-
comitant medications with a specific indication for the before-
mentioned conditions.
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ This large, international cohort study confirms the
effectiveness and safety of the all-oral combination of SOF
and RBV for treatment of HCV GT2.
▸ The results from recent phase III studies demonstrating that
SOF and velpatasvir is superior to SOF plus RBV must be
confirmed in real-world studies.
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Efficacy and safety endpoints
HCV RNA was determined according to local standard molecu-
lar tests. Primary efficacy endpoint was SVR12 defined as HCV
RNA below the lower limit of quantification or undetectable at
least 64 days after treatment was discontinued (allowing for
window around usual clinic visits). An analysis was performed of
the evaluable population (EP), defined as the group of patients
who have completed either 12-week or 16-week regimen and
have the final treatment outcome available, including those who
were lost to post-treatment follow-up (counted as treatment fail-
ures). An analysis of the per protocol (PP) population was also
performed in the group of patients who completed 12-week or
16-week regimen and have virological outcomes available.
Adverse events (AEs) were recorded in the medical record
regularly at patient visits. Anaemia was defined as either anaemia
reported as an AE or documented RBV dose modification, appli-
cation of erythropoietin or transfusion. Serious AEs/suspected
unexpected serious adverse reactions were reported by sites by
submission of Voluntary Form FDA3500 (MedWatch) to the
Clinical Coordinating Center at the University of Florida.
Statistical analysis
Demographics, baseline laboratory values, outcomes and fre-
quencies of AEs were collected and analysed for the EP accord-
ing to discrete subpopulations of interest, particularly based on
the duration of treatment (12 and 16 weeks). Virological out-
comes and associations between sustained virological response
(SVR) and baseline patient characteristics, baseline RBV dose
(per kg), RBV management during treatment and treatment dur-
ation were explored among PP patients.
Multivariable analyses with Firth’s penalised estimation of pre-
dictors of sustained virological response were run for the SOF–
RBV patients and measures of association between selected covari-
ates and SVR were estimated with logistic regression with the pre-
dictor of interest with ‘minimal’ covariate adjustment for age and
gender. A set of univariable logistic models as well as a set of multi-
variable logistic models with the predictor of interest, age, gender
and prior antiviral treatment experience and cirrhotic status in the
model were performed for sensitivity analysis (not shown). The set
of predictor variables were selected a priori based on a consensus
of clinical expertise and included the well-established baseline cov-
ariates associated with SVR: cirrhosis status, gender, age, race,
model for end-stage liver disease (MELD), albumin (g/dL), platelet
count (1000/μL), creatinine clearance, total bilirubin (mg/dL),
haemoglobin (g/dL), international normalised ratio, RBV dose at
baseline (mg/kg) and RBV dose reduction. The results are
presented with an OR and 95% CIs. Patients who prematurely
discontinued due to any reason (there are no discontinuations due
to lack of efficacy) or were lost to follow-up are excluded from the
multivariable analyses. Analyses were performed using SAS soft-
ware V.9.4 (SAS Institute, Cary, North Carolina, USA).
Study oversight
All patients provided written informed consent prior to their
participation. The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines.
All authors had access to the data and approved the final version
of the manuscript.
RESULTS
Patient population
Between December 2013 and April 2015, 361 patients with
chronic HCV GT2 infection with no history of liver
transplantation or prior DAA therapy initiated treatment with
SOF and RBV. Of those, 24 discontinued early for the following
reasons: AEs 10 (2.8%), lost to on-treatment follow-up 9
(2.5%), non-compliance 3 (1%) and 2 (<1%) due to other
reasons. Of 337 patients who completed treatment, 10 patients
who received unconventional treatment durations (neither 12
nor 16 weeks) and 6 patients who still continued in post-
treatment follow-up were excluded from our analyses. The EP
thus includes 321 patients. Of those, 307 had completed treat-
ment (for either 12 or 16 weeks) and ended post-treatment
follow-up, and 14 patients were lost to post-treatment follow-up
(figure 1).
Demographic and clinical characteristics of the study partici-
pants are shown in table 1. The median age of the patients was
59 years. The majority was white (276/321; 86.0%) and male
(196/321; 61.1%). 30.5% of the patients were experienced to
prior treatment with PegIFN and RBV. Cirrhosis was present in
86 of 321 (26.8%) patients. Of these, 36 (41.9%) had evidence
of current or prior decompensation. Compared with patients
treated for 12 weeks, the proportion of patients with prior treat-
ment experience and cirrhosis was higher in the group who
received 16 weeks of treatment. Among cirrhotics, a higher per-
centage in the 16-week group had received prior therapy (17/24
(70.8%) vs 30/62 (48.4%)) and had MELD scores of ≥10
(57.9% vs 39.5%); also, the mean platelet counts were lower in
patients with cirrhosis who received the extended treatment
duration (77 vs 105.5×103/μL).
Efficacy
The SVR12 rates for the EP and for the PP population, stratified
by prior treatment (treatment naïve, experienced) and cirrhosis
status are shown in table 2. Overall, 283 of 321 patients
(88.2%) achieved a SVR12 in the EP, while 283 of 307 (92.2%)
in the PP population had a SVR12 (table 2). In the EP analysis,
283 (88.2%) and 38 (11.8%) of 321 patients received SOF and
RBV for 12 or 16 weeks, respectively. The PP population
included 271 (88.3%) and 36 (11.7%) patients treated for 12
and 16 weeks, respectively. Among GT2-infected patients
treated for 12 weeks, the overall SVR12 rate (EP) was 88.3%
(250/283) and 86.8% (33/38) in those treated for 16 weeks.
Corresponding SVR12 rates in the PP population were 92.3%
(250/271) and 91.7% (33/36), respectively. In patients without
cirrhosis, SVR12 (EP) was 91.0% (201/221) in patients who
received 12 weeks of SOF and RBV and 92.9% (13/14) among
patients treated for 16 weeks. SVR12 rates (EP) in patients
with cirrhosis treated for 12 or 16 weeks were 79.0% (49/62)
and 83.3% (20/24), respectively. In the PP population, 93.9%
(201/214) and 100% (13/13) of patients without cirrhosis and
86.0% (49/57) and 87.0% (20/23) of patients who received 12
or 16 weeks of treatment achieved a SVR12. SVR12 rates for
the EP and PP population, further stratified by prior treatment
status (naïve vs experienced) are shown in table 2. SVR12 rates
(PP) were similar in US versus European patients; 9 of 10
(90%) (PP) of the patients treated in Europe and 274 of 311
(88.1%) of the US patients achieved a virological response.
We also investigated the impact of baseline haemoglobin,
baseline RBV dose and RBV dose reduction on SVR12. Figure 2
shows the probability of achieving a SVR12 by RBV dose at
baseline (mg/kg). Lower baseline RBV doses were associated
with a lower probability of SVR12 and optimal chances for
SVR12 are predicted for baseline RBV doses of 15 mg/kg body-
weight (BW) and higher. In patients with RBV dose reductions,
PP SVR12 rates were 94.0% (78/83) compared with 91.5%
(205/224) in patients without RBV dose reductions. In patients
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with cirrhosis, the corresponding SVR12 rates were 92.9% (28/28)
and 82.7% (43/52), respectively.
Of the 38 patients who did not achieve a SVR12, 24 had a
virological failure and 14 were lost to post-treatment follow-up.
Relapse was the most common reason for virological failure
(21/24, 87.5%); viral breakthrough was reported in two and
non-response in one patient (table 2).
In the multivariable minimally adjusted regression analysis,
the absence of cirrhosis and higher serum albumin demonstrated
a significant association with SVR12 (OR 2.4, 95% CI 1.02 to
5.54; and OR 3.2, 95% CI 1.51 to 6.9, respectively) (figure 3).
Baseline haemoglobin and RBV dose reductions did not im-
pact SVR12 rates. However, there was a small, although statistic-
ally significant (p=0.024) impact of higher baseline RBV dose
(mg/kg) and SVR12 (OR 1.2, 95% CI 1.02 to 1.33). Sensitivity
analysis was performed employing univariable analysis as well as
multivariable analysis adjusting for cirrhosis status and prior treat-
ment experience in addition to age and sex (data not shown).
Both methods support the findings of the minimally adjusted
model. There were no significant changes in MELD score, platelet
count, total bilirubin and albumin in patients with cirrhosis who
achieved SVR12 compared with those with virological failure
within the study’s treatment and follow-up period (see online
supplemental figure S1). The change was measured between the
values recorded prior to treatment start and values recorded
10 weeks or later (latest available) after treatment end.
Safety
Only 10 of 361 (2.8%) patients discontinued treatment prema-
turely due to an AE. Of those, eight patients had liver cirrhosis.
The reasons for drug discontinuation, each reported in one of
the patients, included anaemia, anxiety, chest pain, hepatic
encephalopathy, multiorgan failure and cardiac arrest, while two
patients each were reported to have decreased drug tolerance
and myocardial infarction.
Six patients (1.9%), all patients with cirrhosis, who started
treatment with SOF and RBV died. The reported cause of death
was multiorgan failure in three patients, cardiac arrest in two
patients and hepatic encephalopathy in one patient. All deaths
were considered unrelated to the antiviral medication by the treat-
ing physicians. Of the patients with multiorgan failure, one had a
myocardial infarction; another patient discontinued SOF and RBV
on treatment day 2 due to multiorgan failure and another patient
had a multiorgan failure 27 days after the last intake of SOF and
RBV. Of the patients with cardiac arrest, one patient had a car
accident with cardiac arrest reported as a cause of death the subse-
quent day; another patient had a HCC at enrollment in HCV–
TARGET and cardiac arrest was reported as a cause of death on
treatment day 98. None of the two patients with reported cardiac
arrest had received amiodarone or calcium channel blockers.
Reported heart disease-related medications included nadolol and
benazepril in one, and nadolol, spironolactone and furosemide in
the other patient. The patient with hepatic encephalopathy had a
history of hepatic decompensation at initiation of treatment and
expired on treatment day 98. The event was not considered to be
treatment related by the treating physician.
AEs were reported in 268/321 (83.5%) patients of the EP
(table 3). Most common AEs, reported in ≥10% of the patients,
included fatigue, anaemia, nausea, headache, insomnia, rash,
influenza-like illness and dyspnoea. Anaemia was reported in 68
patients (21.2%) and was more frequent in patients who were
treated for 16 weeks, compared with those who received
12 weeks of therapy (36.8% vs 19.1%, respectively), possibly
also attributable to the higher proportion of patients with liver
Figure 1 Patient disposition. DAA, direct-acting antiviral; f/u, follow-up; OLT, orthotopic liver translantation; SVR12, sustained virological response
12 weeks after therapy.
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cirrhosis in the extended treatment group. Anaemia was
managed mostly with RBV dose reductions in 17.8%. Blood
transfusions or the use of erythropoietin was documented in
2.5% and 3.1% of the patients, respectively.
DISCUSSION
The results of this large, international observational study that
included 321 HCV GT2-infected HCV-TARGET participants
demonstrate a high efficacy of SOF and RBV. Overall SVR12
rate was 88.2% (283/321) and the PP SVR12 rate (only includ-
ing patients who completed 12-week or 16-week treatment dur-
ation and have virological SVR12 results available) was 92.2%
(283/307). Both treatment durations of SOF in combination
with weight-based RBV in this clinical practice setting were well
tolerated.
Several randomised phase III trials investigated SOF in com-
bination with RBV for 12 weeks in HCV GT2-infected patients
with or without liver cirrhosis. FISSION was a randomised non-
inferiority trial comparing SOF and RBV for 12 weeks with
PegIFN plus RBV for 24 weeks in treatment-naïve GT2-infected
patients. Response rates were 97% (58/61) in patients without
cirrhosis and 83% (10/12) in patients with cirrhosis who
received SOF and RBV, compared with 81% (44/54) and 62%
(8/13) in respective groups who received PegIFN and RBV.11
POSITRON, a placebo-controlled trial, included 109
GT2-infected patients who were ineligible for treatment with
PegIFN . Response rates for the 12-week regimen were 92%
(85/92) and 94% (16/17) in patients without cirrhosis and
patients with cirrhosis, respectively.12 The VALENCE trial evalu-
ated SOF with RBV for 12 weeks in GT2-infected patients.
High response rates were observed across the different sub-
groups: 97% (29/30) and 91% (30/33) among treatment-naïve
and treatment-experienced patients without liver cirrhosis, and
100% (2/2) and 88% (7/8) in treatment-naïve or
treatment-experienced patients with cirrhosis.13 FUSION was a
randomised, double-blinded trial that evaluated 12 or 16 weeks
of treatment with SOF and RBV in patients who failed prior
interferon-based therapy (relapsers and non-responders). In
patients without cirrhosis, response rates observed with
16 weeks did not substantially differ from those obtained with
12 weeks of treatment (90% (26/29) vs 92% (24/26)). In
patients with liver cirrhosis, however, the response rate was
78% (7/9) in patients treated for 16 weeks compared with 60%
(6/10) in patients treated for 12 weeks.12 A recent phase IIIb
Table 1 Baseline demographic and clinical characteristics among patients with genotype 2 (GT2) infection who completed therapy with
sofosbuvir (SOF) and ribavirin (RBV)
Overall cohort Cirrhotics
Characteristic
SOF plus RBV for
12 weeks (n=283)
SOF plus RBV for
16 weeks (n=38) Total (n=321)
SOF plus RBV for
12 weeks (n=62)
SOF plus RBV for
16 weeks (n=24) Total (n=86)
Median age (range), years 59.0 (21–80) 62.5 (30–78) 59.0 (21–80) 60 (40–78) 62 (46–78) 60.5 (40–78)
18–39 22 (7.8%) 2 (5.3%) 24 (7.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
40–64 202 (71.4%) 22 (57.9%) 224 (69.8%) 49 (79.0%) 16 (66.7%) 65 (75.6%)
65+ 59 (20.8%) 14 (36.8%) 73 (22.7%) 13 (21%) 8 (33.3%) 21 (24.4%)
Male sex, n (%) 174 (61.5%) 22 (57.9%) 196 (61.1%) 40 (64.5%) 14 (58.3%) 54 (62.8%)
Race, n (%)
White 243 (85.9%) 33 (86.8%) 276 (86.0%) 55 (88.7%) 22 (91.7%) 77 (89.5%)
Black 16 (5.7%) 2 (5.3%) 18 (5.6%) 2 (3.2%) 0 (0.0%) 2 (2.3%)
Other 24 (8.5%) 3 (7.9%) 27 (8.4%) 5 (8.1%) 2 (8.3%) 7 (8.1%)
Hispanic ethnicity, n (%) 22 (7.8%) 5 (13.2%) 27 (8.4%) 7 (11.3%) 3 (12.5%) 10 (11.6%)
Prior HCV treatment, n (%)
Naive 205 (72.4%) 18 (47.4%) 223 (69.5%) 32 (51.6%) 7 (29.2%) 39 (45.3%)
Experienced 78 (27.6%) 20 (52.6%) 98 (30.5%) 30 (48.4%) 17 (70.8%) 47 (54.7%)
Cirrhosis, n (%) 62 (21.9%) 24 (63.2%) 86 (26.8%) 62/62 (100%) 24/24 (100%) 86/86 (100%)
History of hepatic decompensation,
n (%)
28 (9.9%) 12 (31.6%) 40 (12.5%) 25 (40.3%) 11 (45.8%) 36 (41.9%)
MELD≥10 (among cirrhotics)* 17/43 (39.5%) 11/19 (57.9%) 28/62 (45.2%) 17/43 (39.5%) 11/19 (57.9%) 28/62 (45.2%)
HCV GT2 subtype
2a 18 (6.4%) 3 (7.9%) 21 (6.5%) 3 (4.8%) 2 (8.3%) 5 (5.8%)
2b 125 (44.2%) 22 (57.9%) 147 (45.8%) 31 (50.0%) 13 (54.2%) 44 (51.2%)
2c 2 (0.7%) 0 (0.0%) 2 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
2d 1 (0.4%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Not reported 137 (48.4%) 13 (34.2%) 150 (46.7%) 28 (41.2%) 9 (37.5%) 37 (43%)
EU patients 11 (4.8%) 1 (2.7%) 12 (3.8%) 4 (6.4%) 1 (4.2%) 5 (5.8%)
HCV RNA (median), log10 IU/mL 6.3 6.4 6.3 5.9 6.0 5.9
Total bilirubin, median (range),
mg/dL
0.6 (0.1–6.2) 0.8 (0.3–5.5) 0.6 (0.1–6.2) 1.0 (0.2–6.2) 1.2 (0.3–5.5) 1.0 (0.2–6.2)
Albumin, median (range), g/dL 4.2 (2.2–5.4) 3.8 (2.6–4.6) 4.2 (2.2–5.4) 3.7 (2.2–4.9) 3.7 (2.6–4.5) 3.7 (2.2–4.9)
ALT, median (range), IU/L 53.0 (9.0–554.0) 62.5 (20.0–428.0) 53.0 (9.0–554.0) 49.0 (24.0–278.0) 81.0 (20.0–428.0) 64.0 (20.0–428.0)
Platelet count, median (range)
(×103)/mL
189 (35.0–407.0) 111 (34.0–302.0) 185 (34.0–407.0) 105.5 (35.0–307.0) 77 (34.0–229.0) 100 (34.0–307.0)
*In patients with available score.
ALT, alanine-aminotransferase; EU, European Union; MELD, model for end-stage liver disease.
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trial (BOSON) investigated SOF and RBV for 16 or 24 weeks
and SOF in combination with PegIFN and RBV in
interferon-experienced patients with compensated liver cirrho-
sis. Response rates were similar across the different treatment
groups: 87% (15/16) and 100% (17/17) in patients treated with
SOF and RBV for 16 or 24 weeks, and 94% (15/16) in patients
treated with SOF, PegIFN and RBV.23 Across these phase III
studies, high response rates (90–97%) were consistently
observed in patients with GT2 and without cirrhosis treated
with SOF and RBV for 12 weeks. However, numbers of patients
with liver cirrhosis enrolled into these trials were small, and
response rates in this patient group ranged from 60% in
FUSION to >87% in other phase III studies. Also, the compari-
son and interpretation of different treatment durations (12 vs
16 weeks in FUSION or 16 vs 24 weeks in BOSON) were
limited by the small number of patients with cirrhosis included
into the respective treatment groups.
Few studies have reported real-world, clinical practice out-
comes for SOF and RBV for treatment of HCV GT2. A recent
observational study (TRIO Health) evaluated the efficacy of
SOF and RBV for 12 weeks in a real-world population of
GT2-infected patients.18 In this study, SVR12 rates intent-to-
treat (ITT) were considerably lower in patients with liver cirrhosis
compared with patients without cirrhosis (71% (32/45) vs 89%
(140/157), respectively). Another observational study investigated
the effectiveness of SOF and RBV in GT2-infected US veterans.19
Observed response rates among 619 veterans with GT2 infection
were generally lower than in pivotal trials and reported SVR rates
were 81.6% and 70.9% in treatment-naïve and
treatment-experienced patients without liver cirrhosis, respectively.
In patients with advanced liver disease, SVR12 rates were 58.2%
in those with a FIB-4 >3.25, 53.1% in those with an aspartate
aminotransferase to platelet ratio index (APRI)>2 and 44.4% in
patients with a history of decompensated liver disease.
In the present clinical practice study, in PP analysis, SVR12
rates in patients without cirrhosis were comparable with those
reported in phase III clinical trials. SVR12 rates in patients
without cirrhosis were 93.9% and 100% for 12 or 16 weeks of
therapy, respectively. In line with other real-world studies, SVR12
rates were lower in patients with liver cirrhosis (86% and 87%).
Despite the large number of patients with cirrhosis included into
this study, the number of patients with cirrhosis again was not
large enough to decide whether treatment prolongation from 12
to 16 weeks has a significant impact. Also, baseline variables
among patients with cirrhosis treated for 12 or 16 weeks were
not balanced as a higher proportion of patients who received the
extended treatment duration had more advanced liver disease.
Although the study only included a small number of European
GT2-infected patients, SVR12 rates appeared to be similar in US
and non-US patients. Baseline haemoglobin levels and RBV dose
reductions did not impact SVR12 rates. However, there was a
significant impact of lower baseline RBV doses on SVR12 with
optimal chances for SVR12 predicted for baseline RBV doses of
15 mg/kg bodyweight and higher. Compared with the 12-week
treatment duration, anaemia was more frequent in patients
treated with SOF/RBV for 16 weeks (19.1% vs 36.8%) likely
attributable to the higher proportion of patients with more
advanced liver disease in the latter group.
SOF and RBV was generally safe and well tolerated in this
real-world patient population that also included patients with
advanced liver disease (26.8% cirrhotic; prior decompensation
Figure 2 Probability of sustained virological response 12 weeks after
therapy (SVR12) by baseline ribavirin (RBV) dose per kg bodyweight
(BW; mg/kg). CL, confidence limit.
Figure 3 Predictors of sustained virological response (SVR) among genotype 2 (GT2)-infected patients who were treated with sofosbuvir (SOF)
+ribavirin (RBV) and had an available virological outcome (n=307). *Patients who discontinued due to adverse events or were lost to follow-up are
excluded. N, number observed; OR, 95% CI (CL, confidence limit; LCL, lower confidence limit; UCL, upper confidence limit) and p value. **Estimated
with logistic regression with the predictor of interest, age and gender in the model. BW, bodyweight; INR, international normalised ratio; MELD,
model for end-stage liver disease.
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in 12.5%). Most common AEs corresponded to those previ-
ously reported pivotal phase III studies.24 Treatment discon-
tinuation due to AEs was infrequent (2.5%) and most (8/10)
occurred in patients with advanced liver disease. Serious AEs
were reported in <5% of the patients. The somewhat higher
rate compared with pivotal phase III studies might be attribut-
able to the higher proportion of patients with (decompen-
sated) cirrhosis in HCV-TARGET. All six deaths reported in
this study were considered unrelated to the antiviral medica-
tion by the treating physicians. Cardiac arrest was reported as
a cause of death after a road traffic accident and in a patient
with decompensated cirrhosis. Underlying cardiac disease or
intake of amiodarone recently reported to cause symptomatic
bradycardia in combination with SOF was not reported in any
of the two patients. Anaemia was frequent in this real-world
population (21.2%) and mostly managed with RBV dose
reductions.
The strength of the present study is the large number of
patients with GT2 infection, encompassing a high proportion of
patients with cirrhosis (26.8%), and exceeding respective patient
numbers enrolled into any pivotal phase III trials. Central data
collection and abstraction by trained personnel, as well as
ongoing record monitoring, ensured a high quality of the
abstracted data. In addition, the international design confers a
high generalisability of the reported real-world data. As this clin-
ical practice study has a non-randomised, observational design,
differences between treatment groups should be interpreted cau-
tiously. In particular, patients with cirrhosis treated for 16 weeks
had more advanced liver disease than those treated for
12 weeks. Also, the low number of patients treated for 16 weeks
limited, as in respective pivotal studies, again the comparison of
different treatment durations, particularly in patients with liver
cirrhosis. SVR12 has been shown to be associated with improve-
ments in liver function parameters in patients with advanced
liver disease.25 26 Follow-up in this study, however, might not
have been long enough to detect statistically significant differ-
ences in this cohort. Also, information on the presence of
resistance-associated variants in patients with virological failure
is missing. It would have been interesting to investigate whether
some of the treatment failures were attributable to GT2k/1b
recombinant GTs; however, respective sequencing results were
not available.27 As week 4 HCV RNA results were not routinely
collected for patients treated with SOF and RBV, HCV RNA
kinetics could not be investigated in this real-world cohort.
Finally, some attrition bias caused by exclusion of 24 patients
who did not complete treatment with SOF and RBV from the
analysis cannot be excluded.
In summary, in this large, international cohort study, the
all-oral combination of SOF and RBV was safe and effective
for treatment of HCV GT2. While response rates in patients
without cirrhosis were high and comparable with those
reported in clinical trials, the presence of lower albumin
levels and liver cirrhosis was associated with lower SVR12
rates. Larger, randomised trials in patients with cirrhosis are
required to determine the benefit of extended treatment dura-
tions of SOF and RBV in this patient group. Recent studies
showed that combined SOF and valpatasvir (ASTRAL-1,
ASTRAL-2) yielded SVR12 rates of up to 100% in patients
with GT2 and cirrhosis, so that the combination of SOF and
a GT2-active NS5A inhibitor for 12 weeks may be preferable
to SOF and RBV for more than 12 weeks in patients with
GT2 and liver cirrhosis.28 29
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Table 3 Adverse events (AEs) and management of anaemia
Sofosbuvir (SOF) plus ribavirin
(RBV) for 12 weeks (n=283)
SOF plus RBV for 16
weeks (n=38) Total (N=321)
Event N patients (%) N patients (%) N patients (%)
AEs occurred in >10% of patients 234 (82.7) 34 (89.5) 268 (83.5)
Fatigue 110 (38.9) 19 (50.0) 129 (40.2)
Anaemia♦ 54 (19.1) 14 (36.8) 68 (21.2)
Nausea 51 (18.0) 5 (13.2) 56 (17.5)
Headache 44 (15.6) 7 (18.4) 51 (15.9)
Insomnia 41 (14.5) 6 (15.8) 47 (14.6)
Rash 37 (13.1) 7 (18.4) 44 (13.7)
Flu-like symptoms 36 (12.7) 4 (10.5) 40 (12.5)
Dyspnoea 29 (10.3) 5 (13.2) 34 (10.6)
Back pain 10 (3.5) 5 (13.2) 15 (4.7)
Serious AEs* 11 (3.9) 4 (10.5) 15 (4.7)
Anaemia management
RBV dose reduction 45 (15.9) 12 (31.6) 57 (17.8)
Erythropoetin use 7 (2.5) 3 (7.9) 10 (3.1)
Blood transfusion 7 (2.5) 1 (2.6) 8 (2.5)
RBV discontinuation 1 (0.4) 0 (0) 1 (0.3)
*Anaemia (2), abdominal pain (2), chest discomfort (1), chest pain (1), generalised oedema (2), multiorgan failure (1), bacterial peritonitis (2), gastroenteritis (1), upper respiratory tract
infection (1), urinary tract infection (1), fall (1), fluid overload (1), hypovolaemia (1), hepatic encephalopathy (2), depression (1), chronic obstructive pulmonary disease (1) and stent
placement (1). ♦AE of anaemia reported by treatment provider, use of erythropoietin growth factors (such as eryphopoetin) or patient receiving a transfusion.
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